Women were less likely than men to be treated for relapsing multiple sclerosis (MS), French registry data showed. Women had a ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

A short course of Mavenclad can provide long-term reductions in disease activity and disability progression in highly active ...

Nestled in verdant greenery, the innovation hub’s like-minded community, customisable workspaces and proximity to key ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...

Phase IV studies demonstrate the consistent safety and high efficacy of MAVENCLAD on NEDA-3, MRI and cognition outcomes over four yearsNew data on ...

Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and ...

Laurene Powell Jobs, widow of former Apple CEO Steve Jobs and head of the Emerson Collective, is also supporting Harris, along with the former heads of American Express, Merck, Starbucks and Yahoo.

Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the ...